SSCM
ENTA icon

Summit Street Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Summit Street Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-71,675
Closed -$2.1M – 34
2016
Q1 		$2.1M Buy
+71,675
New +$2M 2.19% 28

Other funds holding ENTA

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

Summit Street Capital Management's ENTA Position: Q2 2016 in Review

Summit Street Capital Management sold out of Enanta Pharmaceuticals (ENTA) in Q2 2016, closing a stake of 71,675 shares — an estimated $2.1M sold.

Summit Street Capital Management first reported a position in ENTA in Q1 2016 and held it in 1 quarter. The position peaked at $2.1M in Q1 2016. 129 funds tracked by Wall St. Rank hold ENTA as of Q2 2016.

  • Summit Street Capital Management reported no remaining Enanta Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Summit Street Capital Management sold 71,675 Enanta Pharmaceuticals shares in Q2 2016, an estimated $2.1M.
  • Summit Street Capital Management first reported a position in Enanta Pharmaceuticals in Q1 2016 and held it in 1 quarter.
  • Summit Street Capital Management's Enanta Pharmaceuticals position peaked at $2.1M in Q1 2016.
  • 129 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2016.

Based on Summit Street Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.